Mountain Capital Investment Advisors Inc lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 42.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,020 shares of the biopharmaceutical company’s stock after selling 28,433 shares during the period. Mountain Capital Investment Advisors Inc’s holdings in Pfizer were worth $1,437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Public Employees Retirement Association of Colorado grew its holdings in Pfizer by 5.6% during the first quarter. Public Employees Retirement Association of Colorado now owns 1,047,712 shares of the biopharmaceutical company’s stock worth $34,197,000 after acquiring an additional 55,805 shares during the period. State Street Corp boosted its position in Pfizer by 0.3% in the 1st quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock worth $9,551,162,000 after purchasing an additional 830,299 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in shares of Pfizer by 13.5% during the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 2,702,332 shares of the biopharmaceutical company’s stock worth $88,204,000 after purchasing an additional 321,613 shares during the period. Maverick Capital Ltd. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $297,000. Finally, APG Asset Management N.V. increased its holdings in shares of Pfizer by 129.4% during the 1st quarter. APG Asset Management N.V. now owns 6,955,829 shares of the biopharmaceutical company’s stock valued at $227,038,000 after purchasing an additional 3,924,241 shares in the last quarter. Institutional investors own 69.08% of the company’s stock.

Shares of PFE stock opened at $37.95 on Friday. The company has a market capitalization of $210.88 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16. The firm’s 50-day moving average is $36.59 and its two-hundred day moving average is $36.32. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $40.97.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion for the quarter, compared to analyst estimates of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The company’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.80 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.89 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, November 6th will be given a $0.38 dividend. The ex-dividend date is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a yield of 4.01%. Pfizer’s payout ratio is currently 51.53%.

Several analysts recently commented on PFE shares. Morgan Stanley raised their price target on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. SVB Leerink increased their target price on Pfizer from $39.00 to $42.00 and gave the company a “market perform” rating in a research report on Wednesday, July 29th. ValuEngine lowered shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Mizuho reiterated a “buy” rating and issued a $43.00 price objective on shares of Pfizer in a report on Tuesday, September 15th. Finally, Piper Sandler lifted their price target on Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $39.64.

In related news, Director Ronald E. Blaylock purchased 13,000 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was acquired at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the completion of the transaction, the director now directly owns 4,000 shares in the company, valued at $154,200. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.08% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Insider Trading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.